Defining the impact of chronic lung disease on COVID-19 and developing effective therapies
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:0 publications
Grant number: GA204228
Grant search
Key facts
Disease
COVID-19Start & end year
20222025Known Financial Commitments (USD)
$646,759.51Funder
National Health and Medical Research Council (NHMRC)Principal Investigator
N/A
Research Location
AustraliaLead Research Institution
University of SydneyResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Supportive care, processes of care and management
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
COVID-19 disease is driven by virus-induced, hyper-inflammation that damages the lungs. Patients with chronic lung disease, such as chronic obstructive pulmonary disease (COPD) and tuberculosis (TB), have increased severity of COVID-19 disease. Using our models of TB and smoking-induced COPD, we will define how chronic lung disease increases the severity of COVID-19, how CoV2 infection exacerbates TB and COPD, and identify effective drugs that suppress this inflammatory damage to the lung.